Transcend pursues novel glaucoma treatment
Transcend Medical Inc. has closed a $35 million Series B round and is continuing the development of its Transcend CyPass System, a novel proprietary system for the minimally invasive treatment of glaucoma.
Key Points
Menlo Park, CA-Transcend Medical Inc. has closed a $35 million Series B round and is continuing the development of its Transcend CyPass System, a novel proprietary system for the minimally invasive treatment of glaucoma.
"We are now well-capitalized to accomplish all initial clinical and commercial milestones for the company," said Brian Walsh, president and chief executive officer of Transcend Medical.
The Transcend CyPass System is being developed to both replace current glaucoma therapies and to expand treatment to a much larger patient population. Transcend Medical is focused on a less-invasive procedure using a novel, proprietary system that reduces IOP.
"Today's treatment options for glaucoma are highly limited and only feasible in a limited portion of those affected by the disease worldwide," Dr. de Juan added.
